Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Harvard Bioscience ( (HBIO) ) has issued an update.
On June 18, 2025, Harvard Bioscience, Inc. informed Nasdaq that it is not in compliance with the audit committee requirements due to having only two members following Alan Edrick’s resignation on June 10, 2025. The company plans to appoint a new independent board member to regain compliance and intends to utilize the Nasdaq cure period, which extends until the next annual stockholders’ meeting or June 10, 2026, whichever comes first.
The most recent analyst rating on (HBIO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
Harvard Bioscience’s overall score reflects financial and operational challenges, with declining revenues and profitability weighing heavily. Technical indicators offer some hope for short-term momentum, while the negative valuation and mixed earnings call sentiment further highlight the need for strategic improvements.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. operates in the biotechnology industry, focusing on the development and manufacturing of scientific instruments and systems used in life sciences research.
Average Trading Volume: 11,944,543
Technical Sentiment Signal: Sell
Current Market Cap: $23.51M
Learn more about HBIO stock on TipRanks’ Stock Analysis page.